Net profit fell 6.4% year-on-year to ₹90.5 crore in Q3, compared with ₹96.7 crore in the same period last year.
Revenue, however, rose 10.8% to ₹660 crore from ₹595.7 crore.
Operating performance remained strong during the quarter, with EBITDA climbing 17.3% year-on-year to ₹179 crore from ₹152.7 crore.
As a result, EBITDA margin expanded to 27.1%, compared with 25.6% a year ago.
Following the earnings announcement, shares of Dr Lal PathLabs Ltd. were trading 0.13% higher at ₹ 1,397.
/images/ppid_59c68470-image-176976258909882386.webp)


/images/ppid_a911dc6a-image-177092774715746114.webp)
/images/ppid_a911dc6a-image-177092767520012684.webp)
/images/ppid_a911dc6a-image-177092763347449403.webp)
/images/ppid_a911dc6a-image-177092652580356823.webp)




/images/ppid_a911dc6a-image-177092306157991736.webp)